drugset / Trial / NCT07301229
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)
Timeline
- Start
- 2025-12-29
- Primary completion
- 2028-02-21
- Completion
- 2028-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | 2.5 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 3 mg/kg | Intravenous |